March 17, 2020

As we are all faced with a situation that we couldn’t imagine, we have been receiving questions about edasalonexent and COVID-19 and are providing additional information.

In the Phase 3 PolarisDMD trial of edasalonexent as well as the GalaxyDMD open-label trial, boys are not on steroids.

What we know about edasalonexent is that long-term toxicology studies of edasalonexent at doses that have exposures that exceed those in the clinic have found no evidence for immunosuppression using standard clinical and anatomic physiology methods. We have not found any evidence of immunosuppression or increased infections in clinical studies, now with over 100 patient-years of exposure to edasalonexent.

As always, we are closely monitoring the trial for the safety of the participating boys. To date, we have not identified any safety concerns related to COVID-19. We recommend that families review their local recommendations to reduce risk for boys and their families.

Catabasis® Pharmaceuticals, Inc.

100 High Street, 28th Floor

Boston, MA 02110